The prevalence of childhood hypertension nearly doubled between 2000 and 2020, from 3.40 to 6.53% in boys and from 3.02 to 5.82% in girls. HealthDay News — The prevalence of childhood hypertension is ...

Increased rate of major bleeding and lower mortality rates observed, resulting in greater net clinical benefit.

Proportion of physicians with MHSU care stable prepandemic, then increased, with larger increases seen during first two years of pandemic.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Darzalex Faspro ® is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase that increases permeability of the subcutaneous ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously, ...

HealthDay News — Most countries involved in clinical trials for US Food and Drug Administration approvals do not gain timely physical access to the medicines that they help evaluate, according to a ...

Countries lose measles elimination status when the same strain spreads for 12 months or more. If transmission continues into January (the 1-year mark) the US could lose the designation it has held for ...

HealthDay News — People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. The company announced that ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...